Pertussis Vaccine Market is Segmented By Product Type (DTaP vaccine, Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quaracel, Tdap vaccine), By Vaccine Type(Whole-cell vaccine, Acellular vaccine), By End-User(Hospitals, Clinics, Vaccination Centers, Other), By End-User (Automotive, Aerospace, Safety, Medical, Energy, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Pertussis Vaccine Market Overview
Pertussis Vaccine Market is Predicted to reach at a CAGR 9.6% during the forecast period (2024-2031).
Whooping cough is treated with a pertussis vaccine. This vaccine is only available in conjunction with other vaccines. All children, babies, teenagers, and pregnant women should get vaccinated against pertussis.
Pertussis Vaccine Market
|
Metrics |
Details |
|
Market CAGR |
9.6% |
|
Segments Covered |
By Product Type, By Vaccine Type, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Pertussis Vaccine Market Dynamics
Various factors such as growth in the adoption of pertussis vaccination are expected to drive the market growth.
The adoption of pertussis vaccination is expected to drive the market growth
Pertussis vaccines help protect babies, children, and adults from whooping cough, a respiratory disease. Uncontrollable, violent coughing fits characterize whooping cough. It can lead to severe complications in babies. To protect against whooping cough, all infants, children, and adults should receive a vaccine. The vaccine protects people, particularly infants, from contracting pertussis. Infants are especially vulnerable to whooping cough. Babies with whooping cough are at risk of developing pneumonia (lung infection), uncontrollable shaking, and even brain damage. Because whooping cough begins with mild, cold-like symptoms, many people are unaware they have the infection. Without vaccination, people can easily spread whooping cough to others during the early stages of infection. The CDC recommends whooping cough vaccination for all infants and children, preteens and teenagers, and pregnant women. Adults who never received a Tdap dose should also be immunized against pertussis.
The increasing advantage of the pertussis vaccine is expected to boost market growth. For instance, on January 15th, 2019, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccines, the FDA approved, are used to include repeat vaccination help protect against tetanus, diphtheria, and pertussis. Sanofi manufactures the vaccine under the brand name Adacel. Hence, the growing adoption of pertussis vaccination among people is expected to drive market growth.
The side effects associated with the pertussis vaccine is expected to hamper the market growth
Vaccines, like all medications, may cause side effects. Most side effects are minor, last only a short time, and do not cause long-term problems. The whooping cough vaccine may cause fever, redness, soreness, or swelling where the injection was given, nausea, headache, tiredness, and aching muscles. Serious side effects are extremely uncommon, including severe allergic reactions. These side effects may be more severe in some people. They may temporarily disrupt daily activities. Three out of every hundred people who received Tdap or Td experienced severe arm swelling. One in every 250 adults who receive the Tdap vaccine develops a 102 degrees Fahrenheit or higher fever.
During Tdap clinical trials, two adults experienced temporary nervous system problems. It's unclear whether the vaccine caused this. Tdap or Td vaccination has resulted in severe arm swelling where the shot was administered in rare cases.
COVID-19 Impact Analysis
According to preliminary data, people who have received vaccines have a lower risk of developing severe diseases. Scientists believe vaccines accomplish this by priming the innate immune response to fight. Recent research has looked into inactivated vaccines, particularly diphtheria, tetanus, and pertussis (DTP) vaccines, to see if previous immunizations result in less severe COVID-19 manifestations. A study published in 2020 looked into the bacterial vaccines DTP and concluded that children's possible protection against SARS-CoV-2 could be attributed to cross-reactivity induced by these vaccinations.
Pertussis Vaccine Market Segment Analysis
By product type, the DTaP vaccine segment is expected to dominate the market growth
Diphtheria, tetanus, and pertussis can be prevented with the DTaP vaccine. Diphtheria and pertussis are contagious diseases that spread from person to person. Tetanus enters the body through open wounds or cuts. Diphtheria is a respiratory disease resulting in difficulty breathing, paralysis, heart failure, and death. It's extremely contagious and spreads through coughing and sneezing. Tetanus, also known as lockjaw, is caused by bacteria commonly found in soil. When it enters the body, it releases a toxin that attacks the nervous system, resulting in muscle spasms and death if not treated. Pertussis, also highly contagious, causes severe coughing spasms that make it difficult for infants to eat, drink, or even breathe. It can cause pneumonia, seizures, brain damage, and death.
Children under the age of seven are eligible for DTaP. Tetanus, diphtheria, and pertussis (Tdap and Td) vaccines are available for older children, adolescents, and adults. Children should receive five doses of DTaP at the ages of two months, four months, six months, 15 to 18 months, and four to six years. DTaP can be administered as a separate vaccine or as part of a combination vaccine (a type of vaccine that combines more than one vaccine into one-shot). DTaP can be given alongside other vaccines. Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis are the seven paediatric DTaP vaccines currently licensed and used in the United States.
Pertussis Vaccine Market Geographical Analysis
North America region is expected to hold the largest market share in the global pertussis vaccine market
The increasing incidence of whooping cough is expected to drive the market growth in the forecast period.
The Centers for Disease Control and Prevention (CDC) reported 48,277 cases of pertussis in the United States. As of 2020, the number of pertussis cases in the United States of America was 18,617, accounting for 29.05 percent of all pertussis cases worldwide. Hence, with the increasing incidence of whooping cough, the demand for pertussis vaccine is expected to drive the market growth in this region.
In the United States, there are two vaccines available to help prevent pertussis. The DTaP is for children under seven, and the Tdap is for older children, teens, and adults. These vaccines are highly recommended, and most children and adolescents get them. In 2017, approximately 83% of children aged 19 to 35 months received the DTaP vaccine.
Pertussis Vaccine Market Competitive Landscape
The global pertussis vaccine market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are Sanofi, GlaxoSmithKline, Novartis AG, Seqirus, Merck Sharp & Dohme Corp., and Astellas Pharma US, Inc., KM Biologics
GlaxoSmithKline
Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. The company was founded in 2000. It has headquarters in the United Kingdom.
Product Portfolio: The company's BOOSTRIX is a vaccine for active booster immunization against tetanus, diphtheria, and pertussis in people aged 10 and up. It is available as single-dose vials and prefilled syringes with a 0.5-mL injection suspension.
Key Development: On 23rd June 2021, The new GSK prioritized R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to account for roughly three-quarters of company sales by 2026.
